Shares in Bagsvaerd, Denmark headquartered Novo Nordisk A/S saw a slight decline of 0.17%, ending Wednesday's trading session at $35.20. The stock recorded a trading volume of 4.91 million shares, which was above its three months average volume of 4.46 million shares. The Company's shares have gained 3.04% in the last one month. The stock is trading 4.90% below its 50-day moving average. Moreover, shares of Novo Nordisk, which engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide, have a Relative Strength Index (RSI) of 56.10.
On December 5th, 2016, Novo Nordisk announced the submission of a New Drug Application to the US FDA for semaglutide, a glucagon-like peptide-1 (GLP-1) analog administered once-weekly, for the treatment of adults with type-2 diabetes. The company also submitted a Marketing Authorization Application to the European Medicines Agency for semaglutide. Visit us today and download your complete report on NVO for free at:
New York headquartered Synergy Pharmaceuticals Inc.'s stock declined 2.32%, closing the day at $5.48. A total volume of 2.90 million shares was traded, which was higher than their three months average volume of 2.85 million shares. The Company's shares have advanced 19.65% in the last month and 7.87% in the previous three months. The stock is trading 4.77% above its 50-day moving average and 30.64% above its 200-day moving average. Additionally, shares of Synergy Pharma, which focuses on the development of drugs to treat gastrointestinal disorders and diseases, have an RSI of 54.00.
As per an SEC filing dated November 21st, 2016, Synergy Pharmaceuticals entered into separate, privately-negotiated exchange agreements on November 16th, 2016, and November 21st, 2016, with certain holders of the Company's 7.50% Convertible Senior Notes due 2019. Under the exchange agreements, the Holders agreed to exchange an aggregate principal amount of approximately $20.7 million of Notes and accrued but unpaid interest under the Notes held by them in exchange for 7,555,683 shares of the Company's common stock, par value $0.0001 per share. The transactions are expected to close on or about November 21st, 2016, subject to customary closing conditions. Immediately following the exchange of the Notes contemplated by the exchange agreements, approximately $23.5 million in aggregate principal amount of the Notes will remain outstanding. The complimentary research report on SGYP can be accessed at:
On Wednesday, shares in Morristown, New Jersey headquartered Pernix Therapeutics Holdings Inc. recorded a trading volume of 152,170 shares. The stock ended the day 0.97% higher at $3.11. The Company's shares have advanced 460.36% over the previous three months and 5.42% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 11.52% and 138.19%, respectively. Furthermore, shares of Pernix Therapeutics Holdings, which develops, manufactures, markets, and sells pharmaceutical products, have an RSI of 53.73.
On November 22nd, 2016, Pernix Therapeutics announced the appointment of Gabriel Leung to its Board of Directors, effective immediately. The Board also determined that Mr. Leung is an independent director and appointed him as chairperson of the Nominating Committee and as a member of the Audit and Compensation Committees. Mr. Leung is currently Vice Chairman and Board member of NovoCure Limited, a publicly listed commercial-stage oncology company. Register for free on Stock-Callers.com and download the PDF research report on PTX at:
San Diego, California headquartered Apricus Biosciences Inc.'s stock dropped 3.88%, finishing yesterday's session at $1.24 with a total trading volume of 147,907 shares. The Company's shares are trading below their 50-day moving average by 48.21%. Shares of the Company, which focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology, have an RSI of 26.32.
On December 1st, 2016, Apricus Biosciences announced that the Company received notice on November 30th, 2016, from the NASDAQ Listing Qualifications Staff that due to its non-compliance with the $35 million market value of listed securities requirement, the Company was subject to delisting unless it timely requests a hearing before the NASDAQ Hearings Panel. The Company intends to timely request a hearing before the Panel, which request will stay any delisting action by the NASDAQ Listing Qualifications Staff, pending the Panel`s decision. Get free access to your research report on APRI at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA